

SpectraCure's CEO is leaving the company

Johan Folkunger has today informed the board that he is resigning from his position as CEO of SpectraCure.

Johan Folkunger is leaving SpectraCure as a result of being offered, and having accepted, a new assignment as CEO of another company. Johan Folkunger has a notice period of six months and will continue to work during this time, as agreed with the board. The search for a new CEO will start immediately.

"Johan has done a very good job during his time as CEO of the company and it is a shame that he is leaving us. We continue to have a good relationship and I feel confident that he will continue to contribute to the company, during the time he has left. I also want to congratulate Johan on his new challenges," says Jörgen Wennberg, chairman of SpectraCure AB.

This information is information that SpectraCure is obliged to make public according to the EU Market Abuse Regulation (EU No. 596/2014). The information was submitted, through the provision of the specified contact person, for publication on 2022-07-18 19:10 CET.

For further information, please contact:

SpectraCure AB (publ), Jörgen Wennberg, Chariman of the Board

Jorgen.k.wennberg@icloud.com

Website: www.spectracure.com

SpectraCure is developing a treatment system for the elimination of internal solid cancer tumours. We are initially focusing on recurrent prostate cancer. The hope is to be able to treat other cancers such as breast cancer in the future, pancreas, and head and neck cancer. The approach is based on PDT treatment combined with a proprietary and patented dose planning platform, the IDOSE® software, which makes it possible to control the laser light dose so that the tumour the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to interstitial PDT treatment accurate, precise and safe for every patient. The goal is, in addition to being free of the tumour, to maintain the patient's quality of life, with limited side effects. We conduct clinical trials as an important part in the further development of the Company's treatment system.

The Company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, ca@gwkapital.se, tel +468-503 00 050, and trades under the ticker SPEC.